UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.12B |
| 2 |
Apple
AAPL
|
+$1.08B |
| 3 |
Microsoft
MSFT
|
+$1.05B |
| 4 |
Nike
NKE
|
+$1.03B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$821M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$389M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$383M |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$348M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$263M |
| 5 |
NRG Energy
NRG
|
+$237M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.8% |
| 2 | Financials | 8.25% |
| 3 | Healthcare | 6.4% |
| 4 | Consumer Discretionary | 5.85% |
| 5 | Communication Services | 4.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
6801
AllianzIM U.S. Equity Buffer10 Jan ETF
JANT
$61.7M
| $42.9K | ﹤0.01% |
1,260
-51
| -4% | -$1.69K |
|
6802
InfraCap Equity Income Fund ETF
ICAP
$120M
| $42.9K | ﹤0.01% |
1,744
+1,408
| +419% | +$34.6K |
|
6803
BlackSky Technology
BKSY
$1.14B
| $42.8K | ﹤0.01% |
4,999
-10,503
| -68% | -$98.5K |
|
6804
Hitek Global
HKIT
$30.9M
| $42.8K | ﹤0.01% |
7
+4
| +133% | +$22.1K |
|
|
ELEV
6805
DELISTED
Elevation Oncology
ELEV
| $42.7K | ﹤0.01% |
15,829
-106,736
| -87% | -$402K |
|
|
VBIO
6806
Valion Bio
VBIO
$1.14M
| $42.6K | ﹤0.01% |
+6,432
| New | +$81K |
|
|
BBU
6807
DELISTED
Brookfield Business Partners
BBU
| $42.5K | ﹤0.01% |
2,255
-5,097
| -69% | -$97.8K |
|
6808
Tradr TSLA Bear Daily ETF
TSLQ
$105M
| $42.5K | ﹤0.01% |
+74
| New | +$49.5K |
|
6809
Scully Royalty
SRL
$86.5M
| $42.4K | ﹤0.01% |
5,956
-4,628
| -44% | -$29.4K |
|
6810
NN Inc
NNBR
$298M
| $42.1K | ﹤0.01% |
14,036
+3,432
| +32% | +$12K |
|
6811
Skye Bioscience
SKYE
$16.6M
| $42.1K | ﹤0.01% |
+5,250
| New | +$62.3K |
|
6812
LivePerson
LPSN
$27.3M
| $42K | ﹤0.01% |
4,820
-34,604
| -88% | -$332K |
|
|
NCTY
6813
The9 Ltd
NCTY
$76.5M
| $42K | ﹤0.01% |
+4,808
| New | +$35.1K |
|
|
IVP
6814
DELISTED
Inspire Veterinary Partners
IVP
| $41.8K | ﹤0.01% |
+1,059
| New | +$85.8K |
|
6815
Kewaunee Scientific
KEQU
$109M
| $41.8K | ﹤0.01% |
+885
| New | +$33.5K |
|
6816
Prelude Therapeutics
PRLD
$373M
| $41.7K | ﹤0.01% |
10,934
-4,721
| -30% | -$19.2K |
|
6817
Invesco KBW Premium Yield Equity REIT ETF
KBWY
$307M
| $41.7K | ﹤0.01% |
2,336
-2,556
| -52% | -$44.8K |
|
6818
Dawson Geophysical
DWSN
$148M
| $41.5K | ﹤0.01% |
+21,287
| New | +$38.3K |
|
|
NTZ
6819
Natuzzi
NTZ
$14.8M
| $41.5K | ﹤0.01% |
8,461
+8,424
| +22,768% | +$46.9K |
|
6820
Capricor Therapeutics
CAPR
$242M
| $41.4K | ﹤0.01% |
8,687
+7,187
| +479% | +$40.1K |
|
|
LNKB
6821
DELISTED
LINKBANCORP
LNKB
| $41.3K | ﹤0.01% |
6,741
+1,605
| +31% | +$10.3K |
|
6822
Turkcell
TKC
$4.76B
| $41.2K | ﹤0.01% |
5,440
+2,322
| +74% | +$15.2K |
|
|
NCI
6823
Neo-Concept International Group Holdings
NCI
$27.9M
| $41.2K | ﹤0.01% |
+1,634
| New | +$75.7K |
|
6824
USCB Financial Holdings
USCB
$410M
| $41.1K | ﹤0.01% |
3,206
-7,368
| -70% | -$85.8K |
|
|
BBLG
6825
Bone Biologics
BBLG
$1.66M
| $41.1K | ﹤0.01% |
5,618
+5,518
| +5,518% | +$54.5K |
|
Similar funds
UBS Group's Q2 2024 Portfolio in Review
As of Q2 2024, UBS Group held 10,501 positions worth $405B, up 0.81% from $402B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
UBS Group's Q2 2024 filing shows 1,231 new, 3,688 increased, 4,131 reduced and 1,043 closed positions. Its largest new stake was SLB Ltd: 10,925,731 shares worth $515M. The largest sale was BioMarin Pharmaceuticals, an estimated $389M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.
- UBS Group's largest Q2 2024 buy was SLB Ltd: 10,925,731 shares worth $515M.
- UBS Group added most to NVIDIA in Q2 2024, an estimated $1.12B increase.
- UBS Group's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $389M.
- UBS Group fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $263M.
- UBS Group's ten largest holdings make up 18% of its $405B portfolio in Q2 2024.
- UBS Group opened 1,231 new positions and closed 1,043 in Q2 2024.
- UBS Group's portfolio value rose 0.81% quarter-over-quarter to $405B.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.